WO2009044153A3 - Inhibiteurs et utilisations - Google Patents

Inhibiteurs et utilisations Download PDF

Info

Publication number
WO2009044153A3
WO2009044153A3 PCT/GB2008/003352 GB2008003352W WO2009044153A3 WO 2009044153 A3 WO2009044153 A3 WO 2009044153A3 GB 2008003352 W GB2008003352 W GB 2008003352W WO 2009044153 A3 WO2009044153 A3 WO 2009044153A3
Authority
WO
WIPO (PCT)
Prior art keywords
individual
inhibitor
ecsm2
administering
inhibitors
Prior art date
Application number
PCT/GB2008/003352
Other languages
English (en)
Other versions
WO2009044153A2 (fr
Inventor
Roy Bicknell
John Matthew Jeff Herbert
Dov Joseph Stekel
Original Assignee
Cancer Rec Tech Ltd
Roy Bicknell
John Matthew Jeff Herbert
Dov Joseph Stekel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Rec Tech Ltd, Roy Bicknell, John Matthew Jeff Herbert, Dov Joseph Stekel filed Critical Cancer Rec Tech Ltd
Publication of WO2009044153A2 publication Critical patent/WO2009044153A2/fr
Publication of WO2009044153A3 publication Critical patent/WO2009044153A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3233—Morpholino-type ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention porte sur un procédé d'inhibition de l'angiogenèse tumorale chez un sujet, le procédé comprenant l'administration au sujet d'un inhibiteur d'ECSM2. L'invention porte également sur un procédé consistant à combattre une tumeur solide chez un sujet, le procédé comprenant l'administration au sujet d'un inhibiteur d'ECSM2. L'inhibiteur peut être un anticorps, une molécule de siARN, une molécule anti-sens ou un ribozyme.
PCT/GB2008/003352 2007-10-03 2008-10-03 Inhibiteurs et utilisations WO2009044153A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US99747707P 2007-10-03 2007-10-03
US60/997,477 2007-10-03

Publications (2)

Publication Number Publication Date
WO2009044153A2 WO2009044153A2 (fr) 2009-04-09
WO2009044153A3 true WO2009044153A3 (fr) 2009-06-04

Family

ID=40404000

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/GB2008/003352 WO2009044153A2 (fr) 2007-10-03 2008-10-03 Inhibiteurs et utilisations
PCT/GB2008/003357 WO2009044158A2 (fr) 2007-10-03 2008-10-03 Inhibiteurs et utilisations

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/GB2008/003357 WO2009044158A2 (fr) 2007-10-03 2008-10-03 Inhibiteurs et utilisations

Country Status (1)

Country Link
WO (2) WO2009044153A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108495934B (zh) * 2016-01-15 2021-11-09 塔格瓦克斯有限公司 将腺病毒和化学治疗剂组合用于治疗癌症

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012140414A1 (fr) * 2011-04-11 2012-10-18 Queen Mary And Westfield College University Of London Variants de rhbdf2 et affections malignes ou inflammatoires
CN103131775B (zh) * 2013-02-04 2014-07-09 安徽农业大学 一种检测猪生长性能杂种优势的方法及其应用
WO2015015306A2 (fr) * 2013-06-17 2015-02-05 Korea Advanced Institute Of Science And Technology (Kaist) Procédé de ciblage de rhoj vasculaire pour l'inhibition de l'angiogenèse tumorale
CN103389376B (zh) * 2013-08-21 2015-08-19 中南大学湘雅医院 评估肝细胞癌临床分期和预后的试剂盒及ecscr的应用
WO2015073682A1 (fr) * 2013-11-13 2015-05-21 Oregon Health And Science University Procédés de détection de cellules présentant une infection latente par le vih

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6972179B2 (en) * 2000-07-19 2005-12-06 Exelixis, Inc. RRP sequences and knockout mice and uses thereof
CN1303102C (zh) * 2002-11-13 2007-03-07 中国科学院上海生命科学研究院 利用人和鼠Rhor基因及其编码产物诊断和治疗秃发的方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ARMSTRONG LAURA-JANE ET AL: "ECSM2, an endothelial specific filamin a binding protein that mediates chemotaxis.", ARTERIOSCLEROSIS, THROMBOSIS, AND VASCULAR BIOLOGY SEP 2008, vol. 28, no. 9, September 2008 (2008-09-01), pages 1640 - 1646, XP002520816, ISSN: 1524-4636 *
HUMINIECKI LUKASZ ET AL: "In silico cloning of novel endothelial-specific genes", GENOME RESEARCH, COLD SPRING HARBOR LABORATORY PRESS, WOODBURY, NY, US, vol. 10, no. 11, 1 November 2000 (2000-11-01), pages 1796 - 1806, XP002190090, ISSN: 1088-9051 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108495934B (zh) * 2016-01-15 2021-11-09 塔格瓦克斯有限公司 将腺病毒和化学治疗剂组合用于治疗癌症

Also Published As

Publication number Publication date
WO2009044158A2 (fr) 2009-04-09
WO2009044158A3 (fr) 2009-10-15
WO2009044153A2 (fr) 2009-04-09

Similar Documents

Publication Publication Date Title
WO2007143086A3 (fr) Procédé d'administration
IL231688A0 (en) Dsrna in a human cell to inhibit the expression of eg5 gene, pharmaceutical compound containing it, method and vector
WO2008066642A3 (fr) Systèmes d'administration par voie transdermique
WO2008152131A3 (fr) Inhibition par arni de l'expression du canal alpha-enac
WO2010048585A3 (fr) Composés oligomères et méthodes
WO2007092182A3 (fr) Agents d'interférence arn à usage thérapeutique
WO2008137867A3 (fr) Compositions comportant des agents thérapeutiques mir34 pour traiter le cancer
BR112012015540A2 (pt) composto, uso de composto, método para tratar um individuo, método de inibir janus quinases em um individuo, composição farmacêutica e combinação de produto
WO2009089494A3 (fr) Compositions pharmaceutiques
WO2009039337A3 (fr) Inhibition de l'angiogenèse
EP2385831A4 (fr) Petites molecules inhibitrices de nads, namnat et nmnat
WO2012005550A3 (fr) Composition pharmaceutique pour le traitement d'un carcinome de la vésicule biliaire et méthode d'inhibition de la croissance et des métastases d'un carcinome de la vésicule biliaire et le traitement d'un carcinome de la vésicule biliaire à l'aide de celle-ci
WO2009126650A3 (fr) Inhibition de l’angiogenèse
WO2009044153A3 (fr) Inhibiteurs et utilisations
WO2010077589A3 (fr) Inhibiteurs de stat3 et méthodes thérapeutiques les utilisant
EP2243809A4 (fr) Inhibiteur d'allergène, produit inhibant les allergènes, procédé d'inhibition des allergènes et utilisation en tant qu'inhibiteur d'allergène
WO2010066639A3 (fr) Compositions d'éclaircissement de la peau avec des inhibiteurs d'acétylcholinestérase
WO2010045384A3 (fr) Arn courts en épingles à cheveux destinés à inhiber l’expression des gènes
MX2011006725A (es) Combinacion de inhibidores de aurora cinasa y anticuerpos anti-cd20.
WO2010091308A3 (fr) Composés oligomères et procédés connexes
WO2010085665A3 (fr) Système d'administration ciblée
WO2012037299A3 (fr) Inhibiteurs de l'acide gras synthase
WO2009158374A3 (fr) Inhibiteurs d’activité akt
WO2007106915A8 (fr) Anticorps à efgl 7 et leurs procédés d'utilisation
CA2810119C (fr) Inhibiteurs de clec14a

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08806497

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08806497

Country of ref document: EP

Kind code of ref document: A2